Skip to content
value.today

Sparrow Pharmaceuticals, Inc.

Total raised
$73 M
3 rounds on record
Latest round
$62 M
Jun 2025
First round on record
Dec 2020
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Sparrow Pharmaceuticals, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2025$62 MNo. 3$50 to $250 million

Sparrow Pharmaceuticals, Inc.: Raise no. 3, Jun 2025

Investors in this round

17 investors had bought by the notice of Jul 1, 2025: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$62 M of $121 M offered; $60 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Robert Jacks · Executive Officer, Director
  • Jonathan Root · Director
  • Klaus Veitinger · Director
  • Nanna L?neborg · Director
  • Niall O'Donnell · Director
  • Peter Thompson · Director
  • Zach Scheiner · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total offering amount and total amount sold include the conversion of $18,525,050.35 of outstanding convertible securities.”

Signed by Robert Jacks, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 1, 2025. Read the notice at the SEC.

equitySEC
Apr 2024$10 MNo. 2$10 to $50 million

Sparrow Pharmaceuticals, Inc.: Raise no. 2, Apr 2024

Investors in this round

4 investors had bought by the notice of Apr 12, 2024: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $15 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Robert Jacks · Executive Officer, Director
  • Jonathan Root · Director
  • Klaus Veitinger · Director
  • Niall O'Donnell · Director
  • Peter Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Jacks, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 12, 2024. Read the notice at the SEC.

debt, optionsSEC
Dec 2020$1 MNo. 1Under $2 million

Sparrow Pharmaceuticals, Inc.: Raise no. 1, Dec 2020

Investors in this round

15 investors had bought by the notice of Jan 13, 2021: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $51 M offered; $50 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Katz · Executive Officer
  • Robert Jacks · Executive Officer, Director
  • Klaus Veitinger · Director
  • Peter Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert Jacks, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 13, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Sparrow Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2025).

    SEC Form D · Jul 2025

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Jul 2025

That is all the official record says: Sparrow Pharmaceuticals, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Sparrow Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sparrow Pharmaceuticals, Inc.
NameRoleNamed in
Robert JacksExecutive officerJul 2025
David KatzExecutive officerJan 2021
Jonathan RootDirectorJul 2025
Klaus VeitingerDirectorJul 2025
Nanna L?neborgDirectorJul 2025
Niall O'DonnellDirectorJul 2025
Peter ThompsonDirectorJul 2025
Robert JacksDirectorJul 2025
Zach ScheinerDirectorJul 2025